Compounds > hydrangenol
Page last updated: 2024-12-07

hydrangenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydrangenol: allergen; an isocoumarin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

hydrangenol : A member of the class of dihydroisocoumarins that is 3,4-dihydroisocoumarin substituted by a hydroxy group at position 8 and a 4-hydroxyphenyl group at position 3. It has been isolated from the roots of Scorzonera judaica and exhibits anti-allergic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
ScorzoneragenusA plant genus of the family ASTERACEAE. INULIN and SESQUITERPENES have been found in it.[MeSH]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Scorzonera judaicaspecies[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID119199
CHEMBL ID69299
CHEBI ID5776
CHEBI ID68140
SCHEMBL ID12204955
MeSH IDM0081473

Synonyms (30)

Synonym
8-hydroxy-3-(4-hydroxyphenyl)-3,4-dihydro-1h-isochromen-1-one
hydrangenol
480-47-7
chebi:5776 ,
CHEMBL69299
AC1L3ODH ,
8-hydroxy-3-(4-hydroxyphenyl)-3,4-dihydroisochromen-1-one
tl8pi7phv1 ,
ccris 8569
3,4-dihydro-8-hydroxy-3-(4-hydroxyphenyl)-1h-2-benzopyran-1-one
unii-tl8pi7phv1
1h-2-benzopyran-1-one, 3,4-dihydro-8-hydroxy-3-(4-hydroxyphenyl)-
8-hydroxy-3-(4-hydroxyphenyl)-3,4-dihydro-1h-2-benzopyran-1-one
SCHEMBL12204955
chebi:68140
isocoumarin, 3,4-dihydro-8-hydroxy-3-(p-hydroxyphenyl)-
hydrangenol [inci]
(+/-)-hydrangenol
AKOS028110054
BCP20678
Q5954317
FS-9918
hydranenol
DTXSID20963981
isocoumarin, 3,4-dihydro-8-hydroxy-3-(p-hydroxyphenyl)- (6ci,7ci,8ci); 3,4-dihydro-8-hydroxy-3-(4-hydroxyphenyl)-1h-2-benzopyran-1-one; (+/-)-hydrangenol
bis(cyclopentadienyl)vanadiumiodide
A871960
isocoumarin, 3,4-dihydro-8-hydroxy-3-(p-hydroxyphenyl)- (6ci,7ci,8ci); 3,4-dihydro-8-hydroxy-3-(4-hydroxyphenyl)-1h-2-benzopyran-1-one; ()-hydrangenol
HY-N4028
CS-0024477
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anti-allergic agentA drug used to treat allergic reactions.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
dihydroisocoumarinsAny member of the class of isochromanes that is based on the skeleton of 3,4-dihydroisocoumarin and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID209945Tested for inhibitory activity against T lymphocyte proliferation induced by Con A at 10e-5 M; slightly suppressed the proliferation1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Immunomodulatory activity of thunberginol A and related compounds isolated from Hydrangeae Dulcis Folium on splenocyte proliferation activated by mitogens.
AID308879Increase in 2-Deoxyglucose-uptake in mouse 3T3L1 cells at 100 uM by liquid scintillation counter2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308864Increase in adiponectin gene expression in mouse 3T3L1 cells at 100 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308862Increase in adiponectin release in mouse 3T3L1 cells at 100 uM on day 6 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308850Increase in triglyceride levels in mouse 3T3L1 cells at 1 uM2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308855Increase in adiponectin release in mouse 3T3L1 cells at 3 uM on day 4 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308891Effect on blood triglyceride levels in KKAy mouse at 200 mg/kg, po after 2 weeks2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308857Increase in adiponectin release in mouse 3T3L1 cells at 30 uM on day 4 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308863Increase in adiponectin gene expression in mouse 3T3L1 cells at 30 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308860Increase in adiponectin release in mouse 3T3L1 cells at 10 uM on day 6 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308885Decrease in blood glucose levels in KKAy mouse at 200 mg/kg, po after 2 weeks2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308880Decrease in blood glucose levels in KKAy mouse at 100 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308856Increase in adiponectin release in mouse 3T3L1 cells at 10 uM on day 4 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308867Increase in PPARgamma2 gene expression in mouse 3T3L1 cells at 100 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308896Decrease in blood free fatty acid levels in KKAy mouse at 100 mg/kg, po after 2 weeks2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308853Increase in triglyceride levels in mouse 3T3L1 cells at 30 uM2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308878Increase in 2-Deoxyglucose-uptake in mouse 3T3L1 cells at 30 uM by liquid scintillation counter2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308866Increase in PPARgamma2 gene expression in mouse 3T3L1 cells at 30 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308897Decrease in blood free fatty acid levels in KKAy mouse at 200 mg/kg, po after 2 weeks2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308859Increase in adiponectin release in mouse 3T3L1 cells at 3 uM on day 6 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308870Decrease in IL6 gene expression in mouse 3T3L1 cells at 100 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID38025Tested for inhibitory activity against B lymphocyte proliferation induced by LPS at 10e-5 M; significantly potentiated the proliferation1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Immunomodulatory activity of thunberginol A and related compounds isolated from Hydrangeae Dulcis Folium on splenocyte proliferation activated by mitogens.
AID308869Decrease in IL6 gene expression in mouse 3T3L1 cells at 30 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308887Effect on blood triglyceride levels in KKAy mouse at 200 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308854Increase in triglyceride levels in mouse 3T3L1 cells at 100 uM2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308890Effect on blood triglyceride levels in KKAy mouse at 100 mg/kg, po after 2 weeks2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308882Decrease in blood glucose levels in KKAy mouse at 100 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308884Decrease in blood glucose levels in KKAy mouse at 100 mg/kg, po after 2 weeks2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308894Decrease in blood free fatty acid levels in KKAy mouse at 100 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308895Decrease in blood free fatty acid levels in KKAy mouse at 200 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308873Increase in GLUT4 gene expression in mouse 3T3L1 cells at 100 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308851Increase in triglyceride levels in mouse 3T3L1 cells at 3 uM2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308861Increase in adiponectin release in mouse 3T3L1 cells at 30 uM on day 6 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308888Effect on blood triglyceride levels in KKAy mouse at 100 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308877Increase in 2-Deoxyglucose-uptake in mouse 3T3L1 cells at 10 uM by liquid scintillation counter2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308883Decrease in blood glucose levels in KKAy mouse at 200 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308886Effect on blood triglyceride levels in KKAy mouse at 100 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308892Decrease in blood free fatty acid levels in KKAy mouse at 100 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308875Increase in 2-Deoxyglucose-uptake in mouse 3T3L1 cells at 1 uM by liquid scintillation counter2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308872Increase in GLUT4 gene expression in mouse 3T3L1 cells at 30 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308876Increase in 2-Deoxyglucose-uptake in mouse 3T3L1 cells at 3 uM by liquid scintillation counter2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308858Increase in adiponectin release in mouse 3T3L1 cells at 100 uM on day 4 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308852Increase in triglyceride levels in mouse 3T3L1 cells at 10 uM2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID209949Tested for inhibitory activity against T lymphocyte proliferation induced by PHA; showed no suppressive effect1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Immunomodulatory activity of thunberginol A and related compounds isolated from Hydrangeae Dulcis Folium on splenocyte proliferation activated by mitogens.
AID308889Effect on blood triglyceride levels in KKAy mouse at 200 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308881Decrease in blood glucose levels in KKAy mouse at 200 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308893Decrease in blood free fatty acid levels in KKAy mouse at 200 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (25.00)18.7374
1990's8 (40.00)18.2507
2000's4 (20.00)29.6817
2010's2 (10.00)24.3611
2020's1 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.19 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index218.50 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (66.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aa 861
2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone: structure given in first source. docebenone : A member of the class of benzoquinones that is p-benzoquinone in which the hydrogens are substituted by three methyl groups and a 12-hydroxydodeca-5,10-diyn-1-yl group.		1.98101,4-benzoquinones;
acetylenic compound;
primary alcohol		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor
juglone
juglone: structure. juglone : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogen at position 5 has been replaced by a hydroxy group. A plant-derived 1,4-naphthoquinone with confirmed antibacterial and antitumor activities.		1.9910hydroxy-1,4-naphthoquinonegeroprotector;
herbicide;
reactive oxygen species generator
phthalylsulfathiazole
phthalylsulfathiazole: minor descriptor (63-86); on-line & INDEX MEDICUS search SULFATHIAZOLES (66-86); RN given refers to parent cpd. phthalylsulfathiazole : A sulfonamide incorporating 2-carboxybenzamido and 1,3-thiazol-2-yl moieties that is a broad-spectrum antibiotic indicated in the treatment of dysentery, colitis, gastroenteritis and intestinal surgery.		2.02101,3-thiazoles;
dicarboxylic acid monoamide;
sulfonamide antibiotic;
sulfonamide
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		2.0310chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.0210kanamycinsbacterial metabolite
plumbagin
plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.		1.9910hydroxy-1,4-naphthoquinone;
phenols		anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite
azomethane
azomethane: structure		1.9910
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.3920D-glucopyranoseepitope;
mouse metabolite
isocoumarins
Isocoumarins: Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule.. isocoumarin : The simplest member of the class of isocoumarins that is 1H-isochromene which is substituted by an oxo group at position 1.		5.28170isocoumarins
coenzyme a
[no description available]		2.0110adenosine 3',5'-bisphosphatecoenzyme;
Escherichia coli metabolite;
mouse metabolite
p-methoxy-n-methylphenethylamine
p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.		210aromatic ether;
secondary amino compound		metabolite
phyllodulcin, (r)-isomer
phyllodulcin: RN given refers to cpd without isomeric designation; structure		3.4980hydroxybenzoic acid
lunularic acid
lunularic acid: structure given in first source		2.0110stilbenoid
lunularin
lunularin: first source misnames compound; structure in first source		210stilbenoid
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.6830
glycosides
[no description available]		1.9310
chalcone
trans-chalcone : The trans-isomer of chalcone.		2.0110chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.4120stilbene
3,3',4,5'-tetrahydroxystilbene
3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.		210catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		1.9910
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		1.9910homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
thunberginol a
thunberginol A: isolated from Hydrangeae dulcis folium; structure given in first source		3.150
thunberginol b
thunberginol B: isolated from Hydrangeae dulcis folium; structure given in first source		2.9140
thunberginol f
thunberginol F: isolated from Hydrangeae dulcis folium; structure given in first source. thunberginol F : An isobenzofuranone that is 2-benzofuran-1(3H)-one substituted by a hydroxy group at position 7 and a 3,4-dihydroxybenzylidene group at position 3. It has been isolated from the roots of Scorzonera judaica.		3.150catechols;
gamma-lactone;
isobenzofuranone		metabolite;
plant metabolite
calcimycin
Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.		210benzoxazole
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.0210
salicylates
Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.		2.0110monohydroxybenzoateplant metabolite
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		5.15150benzenes;
hydroxycoumarin;
methyl ketone
hyaluronoglucosaminidase
Hyaluronoglucosaminidase: An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Skin Aging
The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.		02.2110
Innate Inflammatory Response
[description not available]		02.1310
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1310
Cancer of Colon
[description not available]		01.9910
Cancer of Intestines
[description not available]		01.9910
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9910
Intestinal Neoplasms
Tumors or cancer of the INTESTINES.		01.9910
Chronic Illness
[description not available]		02.9210
Allergic Contact Dermatitis
[description not available]		02.9210
Dermatitis, Irritant
A non-allergic contact dermatitis caused by prolonged exposure to irritants and not explained by delayed hypersensitivity mechanisms.		02.9210
Dermatitis, Eczematous
[description not available]		02.9210
Dermatitis, Occupational
A recurrent contact dermatitis caused by substances found in the work place.		02.9210
Hand Dermatosis
[description not available]		02.9210
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.9210
Eczema
A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).		02.9210
Hand Dermatoses
Skin diseases involving the HANDS.		02.9210
Dermatitis, Allergic Contact
A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.		02.9210
Contact Dermatitis
[description not available]		02.3820
Dermatitis, Contact
A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.		02.3820